Amgen's erenumab passes Phase II chronic migraine test

Amgen Inc. (NASDAQ:AMGN) said erenumab ( AMG 334) met the primary endpoint of change in monthly migraine days

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE